2022 年第 4 期 第 17 卷

丁苯酞联合丹参川芎嗪注射液治疗急性脑梗死的效果

Effect of butylphthalide combined with salviae miltiorrhizae and ligustrazine hydrochloride injection on acute cerebral infarction

作者：赵红敏1刘丽娜1王静1田惠玉1谢冰川2

英文作者：Zhao Hongmin1 Liu Lina1 Wang Jing1 Tian Huiyu1 Xie Bingchuan2

单位：1河北医科大学第一医院全科医学科，石家庄050031；2河北医科大学第一医院神经内科，石家庄050031

英文单位：1Department of General Practice the First Hospital of Hebei Medical University Shijiazhuang 050031China; 2Department of Neurology the First Hospital of Hebei Medical University Shijiazhuang 050031 China

关键词：急性脑梗死；丁苯酞；丹参川芎嗪；巨噬细胞移动抑制因子

英文关键词：Acutecerebralinfarction;Butylphthalide;Salviaemiltiorrhizaeandligustrazinehydrochloride; Macrophagemigrationinhibitionfactor

• 摘要：

• 目的 探讨丁苯酞联合丹参川芎嗪注射液治疗急性脑梗死的效果。方法 选取河北医科大学第一医院神经内科2020年6月至2021年6月收治的急性脑梗死患者86例,按随机数字表法分为对照组和观察组，各43例。对照组在常规治疗基础上给予丁苯酞氯化钠注射液静脉滴注治疗，观察组在对照组治疗基础上给予丹参川芎嗪注射液静脉滴注治疗，2组均连续治疗2周。比较2组治疗前后血清脂蛋白相关磷脂酶A2（Lp-PLA2）、巨噬细胞移动抑制因子（MIF）、微小RNA-145（miR-145）、miR-146a、B细胞淋巴瘤2（Bcl-2）家族蛋白和Bcl-2相关X蛋白（Bax）水平，以及治疗2周后的临床疗效。结果 治疗前，2组血清Lp-PLA2、MIF、miR-145和Bax水平比较差异均无统计学意义（均P＞0.05）；治疗后，2组血清Lp-PLA2、MIF、miR-145和Bax水平均低于治疗前且观察组Lp-PLA2、miR-145和Bax水平低于对照组［(254±43)μg/L比（379±53）μg/L、(5.1±0.7)比（6.8±1.1）、(0.38±0.28)比（0.83±0.51）］，血清miR-146a和Bcl-2水平均高于治疗前且观察组均高于对照组［(1.36±0.15)比（0.91±0.14）、(0.93±0.29)比（0.72±0.17）］（均P＜0.05）。治疗2周后，观察组总有效率高于对照组［95.4%(41/43)比79.1%（34/43）］(P=0.024)。结论 丁苯酞联合丹参川芎嗪注射液治疗急性脑梗死可提高血清miR-146a、Bcl-2水平，降低血清Lp-PLA2、MIF、miR-145和Bax水平，提高疗效。

• Objective To investigate the effect of butylphthalide combined with salviae miltiorrhizae and ligustrazine hydrochloride injection on acute cerebral infarction. Methods Totally 86 patients with acute cerebral infarction admitted to Department of Neurology, the First Hospital of Hebei Medical University from June 2020 to June 2021 were enrolled. They were randomly divided into control group and observation group, with 43 cases in each group. The control group was treated with butylphthalide sodium chloride injection on the basis of routine treatment, and the observation group was treated with salviae miltiorrhizae and ligustrazine hydrochloride injection on the basis of the control group. Both groups were treated for 2 weeks. The levels of serum lipoprotein related phospholipase A2 (Lp-PLA2), macrophage migration inhibitory factor (MIF), microRNA-145 (miR-145), miR-146a, B cell lymphoma 2 (Bcl-2) family protein and Bcl-2 related X protein (Bax) were compared between the two groups before and after treatment, and the clinical efficacy after 2 weeks of treatment were compared. Results Before treatment, there were no significant differences in levels of serum Lp-PLA2, MIF, miR-145 and Bax between the two groups (all P>0.05). After treatment, levels of serum Lp-PLA2, MIF, miR-145 and Bax in both groups were lower than those before treatment, and levels of Lp-PLA2, miR-145 and Bax in the observation group were lower than those in the control group ［(254±43) μg/L vs (379±53)μg/L, (5.1±0.7) vs (6.8±1.1), (0.38±0.28) vs (0.83±0.51)］; levels of serum miR-146a and Bcl-2 in both groups were higher than those before treatment, and those in the observation group were higher than those in the control group ［(1.36±0.15) vs (0.91±0.14), (0.93±0.29) vs (0.72±0.17)］(all P<0.05). After 2 weeks of treatment, the total effective rate in the observation group was higher than that in the control group ［95.4%(41/43) vs 79.1%(34/43)］(P=0.024). Conclusions Butylphthalide combined with salvia miltiorrhiza and ligustrazine hydrochloride injection in the treatment of acute cerebral infarction can effectively increase levels of serum miR-146a and Bcl-2, reduce levels of serum Lp-PLA2, MIF, miR-145 and Bax, and improve the curative effect.